Nicholson Nur's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Mar 14, 2024
- Accession no.
- 0001127602-24-010127
- Filed
- Mar 14, 2024
- Trade date
- Mar 13, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $645.8K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nicholson NurCIK 0001827317 | Officer (Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 13, 2024 | Common Stock | SSaleDisposed | −7,768 | $57.31 | −$445,184.08 | 59,739 | Direct | |
| Mar 13, 2024 | Common Stock | SSaleDisposed | −3,452 | $58.13 | −$200,664.76 | 56,287 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.